Best for
Mobile
How to buy Regeneron Pharmaceuticals shares | $544.1
Own Regeneron Pharmaceuticals shares in just a few minutes. Share price changes are updated daily.
Posted
Fact checked
Regeneron Pharmaceuticals, Inc (REGN) is a leading biotechnology business based in the US. It opened the day at $558.91 after a previous close of $548.2. During the day the price has varied from a low of $542.14 to a high of $556.95. The latest price was $544.1 (25 minute delay). Regeneron Pharmaceuticals is listed on the NASDAQ and employs 8,314 staff. All prices are listed in US Dollars.
How to buy shares in Regeneron Pharmaceuticals
- Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
- Open your account. You'll need your ID, bank details and national insurance number.
- Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
- Search the platform for stock code: REGN in this case.
- Research Regeneron Pharmaceuticals shares. The platform should provide the latest information available.
- Buy your Regeneron Pharmaceuticals shares. It's that simple.
What's in this guide?
- Can I buy shares in Regeneron Pharmaceuticals?
- Regeneron Pharmaceuticals shares summary
- Compare share dealing platforms
- Is Regeneron Pharmaceuticals stock a buy or sell?
- Regeneron Pharmaceuticals performance over time
- Can I short Regeneron Pharmaceuticals shares?
- Is Regeneron Pharmaceuticals suitable for ethical investing?
- Are Regeneron Pharmaceuticals shares over-valued?
- Regeneron Pharmaceuticals's financials
- How volatile are Regeneron Pharmaceuticals shares?
- Does Regeneron Pharmaceuticals pay a dividend?
- Other common questions
Regeneron Pharmaceuticals share price
Use our graph to track the performance of REGN stocks over time.Regeneron Pharmaceuticals shares at a glance
Information last updated 2021-01-26.
| Open | $558.91 |
|---|---|
| High | $556.95 |
| Low | $542.14 |
| Close | $544.1 |
| Previous close | $548.2 |
| Change | $-4.1 |
| Change % | -0.748% |
| Volume | 901,677 |
Information last updated 2021-01-23.
| 52-week range | $328.125 - $664.64 |
|---|---|
| 50-day moving average | $497.7242 |
| 200-day moving average | $565.5821 |
| Wall St. target price | $660.56 |
| PE ratio | 19.709 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $27.286 |
Invest in Regeneron Pharmaceuticals shares with 0% commission
Other fees may apply. Your capital is at risk.
- Unlimited trades, with no dealing charges or management fees
- If your trades get copied you can earn extra money
- Create an account today in a few minutes
Go to site
Capital at risk
Share dealing platform comparison
Table: sorted by promoted deals first
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
Is it a good time to buy Regeneron Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Regeneron Pharmaceuticals price performance over time
Historical closes compared with the last close of $544.1
| 1 month (2020-12-24) | 11.28% |
|---|---|
| 3 months (2020-10-23) | -6.16% |
| 6 months (2020-07-24) | -10.65% |
| 1 year (2020-01-24) | 57.58% |
|---|---|
| 2 years (2019-01-25) | 30.08% |
| 3 years (2018-01-25) | 38.86% |
| 5 years (2016-01-25) | 15.00% |
Is Regeneron Pharmaceuticals under- or over-valued?
Valuing Regeneron Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Regeneron Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Regeneron Pharmaceuticals's P/E ratio
Regeneron Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 20x. In other words, Regeneron Pharmaceuticals shares trade at around 20x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Regeneron Pharmaceuticals's PEG ratio
Regeneron Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.989. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Regeneron Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Regeneron Pharmaceuticals's EBITDA
Regeneron Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is a whopping $3.3 billion.
The EBITDA is a measure of a Regeneron Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
Regeneron Pharmaceuticals financials
| Revenue TTM | $9.2 billion |
|---|---|
| Operating margin TTM | 33.76% |
| Gross profit TTM | $4 billion |
| Return on assets TTM | 12.99% |
| Return on equity TTM | 30.6% |
| Profit margin | 34.14% |
| Book value | $96.011 |
| Market capitalisation | $57.4 billion |
TTM: trailing 12 months
How to short and sell Regeneron Pharmaceuticals shares
- Create a CFD or spread betting account.
- Search for the stock code. E.g. "REGN.US"
- Choose your position size.
- Select "sell" rather than "buy".
- Confirm your position and keep tabs on it. You may wish to set limits on your position.
There are currently 2.2 million Regeneron Pharmaceuticals shares held short by investors – that's known as Regeneron Pharmaceuticals's "short interest". This figure is 14.5% up from 2.0 million last month.
There are a few different ways that this level of interest in shorting Regeneron Pharmaceuticals shares can be evaluated.
Regeneron Pharmaceuticals's "short interest ratio" (SIR)
Regeneron Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Regeneron Pharmaceuticals shares currently shorted divided by the average quantity of Regeneron Pharmaceuticals shares traded daily (recently around 944086.55462185). Regeneron Pharmaceuticals's SIR currently stands at 2.38. In other words for every 100,000 Regeneron Pharmaceuticals shares traded daily on the market, roughly 2380 shares are currently held short.
However Regeneron Pharmaceuticals's short interest can also be evaluated against the total number of Regeneron Pharmaceuticals shares, or, against the total number of tradable Regeneron Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Regeneron Pharmaceuticals's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Regeneron Pharmaceuticals shares in existence, roughly 20 shares are currently held short) or 0.0291% of the tradable shares (for every 100,000 tradable Regeneron Pharmaceuticals shares, roughly 29 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Regeneron Pharmaceuticals.
Find out more about how you can short Regeneron Pharmaceuticals stock.
Regeneron Pharmaceuticals's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Regeneron Pharmaceuticals.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Regeneron Pharmaceuticals's total ESG risk score
Total ESG risk: 22.33
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Regeneron Pharmaceuticals's overall score of 22.33 (as at 01/01/2019) is pretty good – landing it in it in the 27th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Regeneron Pharmaceuticals is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Regeneron Pharmaceuticals's environmental score
Environmental score: 1.51/100
Regeneron Pharmaceuticals's environmental score of 1.51 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Regeneron Pharmaceuticals is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Regeneron Pharmaceuticals's social score
Social score: 13.94/100
Regeneron Pharmaceuticals's social score of 13.94 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Regeneron Pharmaceuticals is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Regeneron Pharmaceuticals's governance score
Governance score: 5.88/100
Regeneron Pharmaceuticals's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Regeneron Pharmaceuticals is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Regeneron Pharmaceuticals's controversy score
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. A high-profile company, Regeneron Pharmaceuticals scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Regeneron Pharmaceuticals has, for the most part, managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
Regeneron Pharmaceuticals, Inc was last rated for ESG on: 2019-01-01.
| Total ESG score | 22.33 |
|---|---|
| Total ESG percentile | 26.82 |
| Environmental score | 1.51 |
| Environmental score percentile | 2 |
| Social score | 13.94 |
| Social score percentile | 2 |
| Governance score | 5.88 |
| Governance score percentile | 2 |
| Level of controversy | 2 |
Regeneron Pharmaceuticals share dividends
We're not expecting Regeneron Pharmaceuticals to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
Regeneron Pharmaceuticals share price volatility
Over the last 12 months, Regeneron Pharmaceuticals's shares have ranged in value from as little as $328.125 up to $664.64. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Regeneron Pharmaceuticals's is 0.2983. This would suggest that Regeneron Pharmaceuticals's shares are less volatile than average (for this exchange).
Win £500 to get your trading started
Subscribe to trending stock alerts for a chance to win
Regeneron Pharmaceuticals overview
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it is developing various product candidates for treating patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva; Mitsubishi Tanabe Pharma; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Vyriad, Inc., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; and BioNTech. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
Frequently asked questions
More guides on Finder
-
How to buy Transportation and Logistics Systems shares
Learn more about Transportation and Logistics Systems’ recent performance and where you can invest in Transportation and Logistics Systems shares. We also run through some helpful rules of thumb for any investor.
-
How to buy Charlie’s Holdings shares
Learn more about Charlie’s Holdings’ recent performance and where you can invest in Charlie’s Holdings shares. We also run through some helpful rules of thumb for any investor.
-
How to buy Lemonade shares
Learn more about Lemonade’s recent performance and where you can invest in Lemonade shares. We also run through some helpful rules of thumb for any investor.
-
How to buy Unity Software shares
Learn more about Unity Software’s recent performance and where you can invest in Unity Software shares. We also run through some helpful rules of thumb for any investor
-
How to buy FuelCell Energy shares
Learn more about FuelCell Energy’s recent performance and where you can invest in FuelCell Energy shares. We also run through some helpful rules of thumb for any investor.
-
How to buy CloudCommerce shares
Learn more about CloudCommerce’s recent performance and where you can invest in CloudCommerce shares. We also run through some helpful rules of thumb for any investor
-
How to buy Zomedica Pharmaceuticals shares
Ever wondered how to buy shares in Zomedica Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Zomedica Pharmaceuticals.
-
How to buy YRC Worldwide shares
Ever wondered how to buy shares in YRC Worldwide? We explain how and compare a range of providers that can give you access to many brands, including YRC Worldwide.
-
How to buy Xeros Technology Group shares
Ever wondered how to buy shares in Xeros Technology Group? We explain how and compare a range of providers that can give you access to many brands, including Xeros Technology Group.
-
How to buy Xpediator shares
Ever wondered how to buy shares in Xpediator? We explain how and compare a range of providers that can give you access to many brands, including Xpediator.
Ask an Expert